Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. (Q44756130)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

27 February 2020

main subject

1 reference

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Richard Allan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Ieuan Jones

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Maria Cristina De Salvo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Lisa F Tan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

28 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

738-745

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23539534%20AND%20SRC:MED&resulttype=core&format=json

Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

The MCID of the transition dyspnea index is a total score of one unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Standardisation of spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Implementation of a Bayesian adaptive design in a proof of concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Methodological issues in therapeutic trials of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744

Increased activation of p38 MAPK in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2012-202744